Cargando…
Thrombosis and Coagulopathy in COVID-19: Current Understanding and Implications for Antithrombotic Treatment in Patients Treated With Percutaneous Coronary Intervention
Coronavirus disease 2019 (COVID-19), a respiratory syndrome, is a global pandemic. Therefore, there is an urgent need to explore mechanisms implicated in the pathogenesis of the disease. Clinical and autopsy studies show a complex chain of events preceding COVID-19-related death. The disease is char...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847976/ https://www.ncbi.nlm.nih.gov/pubmed/33537347 http://dx.doi.org/10.3389/fcvm.2020.599334 |
_version_ | 1783645028511383552 |
---|---|
author | Liu, Hangkuan Wang, Zhijia Sun, Haonan Teng, Tianming Li, Yongle Zhou, Xin Yang, Qing |
author_facet | Liu, Hangkuan Wang, Zhijia Sun, Haonan Teng, Tianming Li, Yongle Zhou, Xin Yang, Qing |
author_sort | Liu, Hangkuan |
collection | PubMed |
description | Coronavirus disease 2019 (COVID-19), a respiratory syndrome, is a global pandemic. Therefore, there is an urgent need to explore mechanisms implicated in the pathogenesis of the disease. Clinical and autopsy studies show a complex chain of events preceding COVID-19-related death. The disease is characterized by endothelial dysfunction, platelet activation, thrombosis, coagulopathy, and multiple organ failure. Globally, millions of patients with coronary heart disease undergo percutaneous coronary intervention (PCI) each year. These patients undergo high-intensity antithrombotic therapy during hospitalization and dual antiplatelet therapy (DAPT) for at least 6 months post PCI. COVID-19 is characterized by changes in platelet counts. Treatment of ischemic events that occur during stent implantation is associated with bleeding complications in patients following PCI complicated by COVID-19. This review summarizes recent progress in activation status and levels of COVID-19-related platelet changes. These findings will provide information on the effectiveness of antithrombotic therapy for the management of platelet changes in COVID-19 patients. |
format | Online Article Text |
id | pubmed-7847976 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-78479762021-02-02 Thrombosis and Coagulopathy in COVID-19: Current Understanding and Implications for Antithrombotic Treatment in Patients Treated With Percutaneous Coronary Intervention Liu, Hangkuan Wang, Zhijia Sun, Haonan Teng, Tianming Li, Yongle Zhou, Xin Yang, Qing Front Cardiovasc Med Cardiovascular Medicine Coronavirus disease 2019 (COVID-19), a respiratory syndrome, is a global pandemic. Therefore, there is an urgent need to explore mechanisms implicated in the pathogenesis of the disease. Clinical and autopsy studies show a complex chain of events preceding COVID-19-related death. The disease is characterized by endothelial dysfunction, platelet activation, thrombosis, coagulopathy, and multiple organ failure. Globally, millions of patients with coronary heart disease undergo percutaneous coronary intervention (PCI) each year. These patients undergo high-intensity antithrombotic therapy during hospitalization and dual antiplatelet therapy (DAPT) for at least 6 months post PCI. COVID-19 is characterized by changes in platelet counts. Treatment of ischemic events that occur during stent implantation is associated with bleeding complications in patients following PCI complicated by COVID-19. This review summarizes recent progress in activation status and levels of COVID-19-related platelet changes. These findings will provide information on the effectiveness of antithrombotic therapy for the management of platelet changes in COVID-19 patients. Frontiers Media S.A. 2021-01-18 /pmc/articles/PMC7847976/ /pubmed/33537347 http://dx.doi.org/10.3389/fcvm.2020.599334 Text en Copyright © 2021 Liu, Wang, Sun, Teng, Li, Zhou and Yang. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Liu, Hangkuan Wang, Zhijia Sun, Haonan Teng, Tianming Li, Yongle Zhou, Xin Yang, Qing Thrombosis and Coagulopathy in COVID-19: Current Understanding and Implications for Antithrombotic Treatment in Patients Treated With Percutaneous Coronary Intervention |
title | Thrombosis and Coagulopathy in COVID-19: Current Understanding and Implications for Antithrombotic Treatment in Patients Treated With Percutaneous Coronary Intervention |
title_full | Thrombosis and Coagulopathy in COVID-19: Current Understanding and Implications for Antithrombotic Treatment in Patients Treated With Percutaneous Coronary Intervention |
title_fullStr | Thrombosis and Coagulopathy in COVID-19: Current Understanding and Implications for Antithrombotic Treatment in Patients Treated With Percutaneous Coronary Intervention |
title_full_unstemmed | Thrombosis and Coagulopathy in COVID-19: Current Understanding and Implications for Antithrombotic Treatment in Patients Treated With Percutaneous Coronary Intervention |
title_short | Thrombosis and Coagulopathy in COVID-19: Current Understanding and Implications for Antithrombotic Treatment in Patients Treated With Percutaneous Coronary Intervention |
title_sort | thrombosis and coagulopathy in covid-19: current understanding and implications for antithrombotic treatment in patients treated with percutaneous coronary intervention |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7847976/ https://www.ncbi.nlm.nih.gov/pubmed/33537347 http://dx.doi.org/10.3389/fcvm.2020.599334 |
work_keys_str_mv | AT liuhangkuan thrombosisandcoagulopathyincovid19currentunderstandingandimplicationsforantithrombotictreatmentinpatientstreatedwithpercutaneouscoronaryintervention AT wangzhijia thrombosisandcoagulopathyincovid19currentunderstandingandimplicationsforantithrombotictreatmentinpatientstreatedwithpercutaneouscoronaryintervention AT sunhaonan thrombosisandcoagulopathyincovid19currentunderstandingandimplicationsforantithrombotictreatmentinpatientstreatedwithpercutaneouscoronaryintervention AT tengtianming thrombosisandcoagulopathyincovid19currentunderstandingandimplicationsforantithrombotictreatmentinpatientstreatedwithpercutaneouscoronaryintervention AT liyongle thrombosisandcoagulopathyincovid19currentunderstandingandimplicationsforantithrombotictreatmentinpatientstreatedwithpercutaneouscoronaryintervention AT zhouxin thrombosisandcoagulopathyincovid19currentunderstandingandimplicationsforantithrombotictreatmentinpatientstreatedwithpercutaneouscoronaryintervention AT yangqing thrombosisandcoagulopathyincovid19currentunderstandingandimplicationsforantithrombotictreatmentinpatientstreatedwithpercutaneouscoronaryintervention |